Novel pharmacologic agents, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, have revolutionized diabetes management, with GLP-1 RAs and SGLT-2 inhibitors in particular demonstrating significant cardiovascular benefit
The complete AOD 9604 dosing guide covers the specifics, but for combination purposes, here is what matters
To combat this, understanding the potential reasons behind weight stagnation and implementing strategic solutions is key
Walk with you through real, physician-led weight lossusing tools like GLP-1 treatments, but never depending on them alone
Work with your doctor to address these issues